Paraoxonase polymorphisms and coronary heart disease. by Durrington, P, Mackness, B, Mackness, M

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. by Thomason, M, Colhoun, H, Livingstone, S, Mackness, M, Betteridge, D, Durrington, P, Hitman, G, Neil, H, Fuller, J

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. by Colhoun, H, Thomason, M, Mackness, M, Maton, S, Betteridge, D, Durrington, P, Hitman, G, Neil, H, Fuller, J

The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. by Soedamah-Muthu, S, Colhoun, H, Thomason, M, Betteridge, D, Durrington, P, Hitman, G, Fuller, J, Julier, K, Mackness, M, Neil, H

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlle... by Colhoun, H, Betteridge, D, Durrington, P, Hitman, G, Neil, H, Livingstone, S, Thomason, M, Mackness, M, Charlton-Menys, V, Fuller, J

Cost-effectiveness of atorvastatin (10mg) in patients with type 2 diabetes without coronary heart disease: CARDS trial analysis and extrapolation by Raikou, M, McGuire, A, Colhoun, H, Betteridge, J, Durrington, P, Hitman, G, Neil, A, Livingstone, S, Thomason, M, Mackness, M, Charlton-Menys, V, Fuller, J, Investigato, C